EBITDA and PAT grew 88 per cent and 114 per cent respectively, reaching Rs 84 crore and Rs 51 crore
Senores Pharmaceuticals continued its strong growth trajectory in the second quarter of FY26, delivering robust financial and operational results across regulated, emerging, and branded generics segments. The research-driven pharmaceutical company, known for developing specialty and complex generics, announced its unaudited results for the quarter and half year ended September 30, 2025.
During Q2 FY26, the company reported consolidated revenue of Rs 162 crore, up 61 per cent year-on-year, with EBITDA rising 113 per cent to Rs 50 crore and PAT surging 131 per cent to Rs 30 crore. For the first half of FY26, consolidated revenue stood at Rs 300 crore, an increase of 66 per cent, while EBITDA and PAT grew 88 per cent and 114 per cent respectively, reaching Rs 84 crore and Rs 51 crore.
The company generated Rs 31.4 crore in operating cash flow during H1 FY26, demonstrating improved cash conversion despite accelerated growth.
Revenue from regulated markets grew 87 per cent year-on-year in Q2 FY26, driven by sustained momentum in own ANDA products and strong operational efficiencies. EBITDA margin in this segment expanded from 36 per cent in Q1 to 44 per cent in Q2 FY26. The company launched eight new products during the quarter, taking its portfolio to 32 own commercial products, 81 approved ANDAs, and 70 pipeline products, alongside 32 commercial CDMO/CMO products and 45 in the pipeline.
The company’s presence across more than 40 countries continued to deliver steady results, with revenues of Rs 32 crore in Q2 FY26 and Rs 61 crore in H1 FY26. EBITDA margin remained stable at around 6%. Senores currently has 394 approved products and 824 under registration for these markets.
The India-focused branded generics business recorded exceptional growth, with revenue rising more than tenfold year-on-year in Q2 FY26 and sevenfold in H1 FY26. Several products under this segment have received approvals from top multi-specialty and specialty hospitals across the country, with a pan-India rollout expected by end of FY26.
Swapnil Shah, Managing Director, Senores Pharmaceuticals said, “Building on the momentum from previous quarters, we delivered another strong performance in Q2 FY26, with robust growth in revenues and profitability. The regulated markets continue to be a key driver, supported by a growing base of our own ANDA products and a strong CDMO pipeline. The branded generics business is scaling up rapidly, with encouraging traction from major hospitals across India. Our focus remains on driving sustainable growth while improving cash flows and operational efficiencies. With new product launches lined up and ongoing capacity enhancements, we are confident of maintaining this momentum through the remainder of FY26 and beyond.”
